# Endo T Male Formulation Against

> Advises against using testosterone preparations formulated for men or compounded by pharmacies in women due to lack of efficacy and safety data specific to female physiology. Triggers include a clinician considering a transdermal patch, gel, or injectable testosterone product that is labeled or compounded for male use.

- Skill: `dromlakhani/endo-t-male-formulation-against` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/endo-t-male-formulation-against`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/endo-t-male-formulation-against/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/endo-t-male-formulation-against

---


# Recommend against using male-formulated testosterone preparations in women

## STEP 1 — Gather Information
Determine patient sex and whether the testosterone product is labeled for male use or compounded by a pharmacy; verify formulation (patch, gel, injectable) and check labeling or compounding source.

## STEP 2 — Rule In / Rule Out
Is the testosterone preparation formulated for men or compounded by a pharmacy? If **yes**, proceed to recommend against use; if **no** (female-specific preparation), consider standard evaluation for testosterone therapy in women.

## STEP 3 — Classify or Stratify
Classify male-formulated or compounded testosterone as **contraindicated** in women due to absent efficacy and safety data; female-specific preparations may be evaluated per guideline 4.1–4.4.

## STEP 4 — Decide
Do not prescribe the male-formulated or compounded testosterone preparation; discuss lack of data, potential risks, and alternative approaches (e.g., approved non-oral preparations if available, or deferring therapy).

## Clinical Guardrails / Mimics / Pitfalls
Do not rely on compounded testosterone for consistent dosing; avoid using male-labeled patches/gels/injectables due to risk of androgen excess; monitor for signs of virilization if inadvertently used; recognize that absence of female-specific data precludes safe use of male formulations.

## Concrete Clinical Example
A 52‑year‑old postmenopausal woman with HSDD inquires about a testosterone gel marketed for men; the clinician advises against its use, explains the lack of safety/efficacy data in women, and suggests discussing approved female‑specific options or avoiding testosterone therapy altogether.

**Source:** Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2260